<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02364297</url>
  </required_header>
  <id_info>
    <org_study_id>ET_GV15</org_study_id>
    <secondary_id>PI 14/00392</secondary_id>
    <nct_id>NCT02364297</nct_id>
  </id_info>
  <brief_title>TIPS in Fundal Variceal Bleeding (the TFB Study)</brief_title>
  <acronym>TFB</acronym>
  <official_title>Efficacy of Early-TIPS in the Treatment of Acute Variceal Bleeding From Gastric Fundal Varices: a RCT vs Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut d'Investigacions Biomèdiques August Pi i Sunyer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital del Mar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut d'Investigacions Biomèdiques August Pi i Sunyer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the last years, important advances have been done in the treatment and prevention of
      fundal variceal bleeding in patients with cirrhosis. Experts agree that the combination of
      pharmacological and endoscopic therapy (with tissue adhesives) should be the first line
      therapy in the acute bleeding episode from isolated gastric varices (IGV1) or type 2
      gastroesophageal varices (GOV2) varices; whereas transjugular intrahepatic portosystemic
      shunt (TIPS) is considered a rescue therapy. TIPS has been shown to effectively prevent
      variceal rebleeding but with a potential increase in the incidence of hepatic encephalopathy
      and/or liver failure. In this sense, a recent randomized controlled trial (RCT) in esophageal
      variceal bleeding showed that an early TIPS, performed during the first 72h after patient
      admission resulted in a significant decrease in failure to control bleeding and early and
      late rebleeding. Moreover, survival was also significantly increased as well as other
      portal-hypertension related complications (ascites, spontaneous bacterial peritonitis,
      hepatorenal syndrome, etc).

      The present study is directed at comparing the outcome of patients with acute bleeding from
      fundal varices (IGV1 or GOV2) treated by standard therapy (vasoactive drugs + endoscopic
      injection of tissue adhesives) with or without early TIPS (performed during the first 1-5
      days after admission). Main end-point will be survival free of variceal rebleeding at 1 year
      from inclusion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined: Absence of rebleeding + survival</measure>
    <time_frame>1 year</time_frame>
    <description>The primary endpoint combines absence of rebleeding + survival during the first 1 year after inclusion in the study. Patients to compare are those with liver cirrhosis and acute bleeding from IGV1 or GOV2 varices initially treated with combined pharmacological and endoscopic therapy. Those patients will be randomized to receive a TIPS or standard medical therapy (pharmacological + endoscopic injection of tissue adhesives)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absence of portal hypertension-related complications (ascites, spontaneous bacterial peritonitis, hepatorenal syndrome)</measure>
    <time_frame>6 weeks and 1 year</time_frame>
    <description>Comparison of the development of portal-hypertension related complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusional requirements</measure>
    <time_frame>6 weeks and 1 year</time_frame>
    <description>We will compare the number of packed red blood cells required by each treatment arms as a surrogate of rebleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>Related and not related to the therapies under study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>1 year</time_frame>
    <description>Including the stay for the index bleed and also readmissions due to complications of liver disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of hospital resources</measure>
    <time_frame>1 year</time_frame>
    <description>Use of hospital resources other than specified in the treatment arms (TIPS, revision of TIPS patency, derivative surgery or additional endoscopic therapy).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Portal Hypertension</condition>
  <condition>Bleeding Gastric Varices</condition>
  <arm_group>
    <arm_group_label>Early TIPS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic injection of tissue adhesives according to the center protocol.
Performance of TIPS in the first 5 days following acute gastric variceal bleeding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic injection of tissue adhesives according to the center protocol.
Standard combined endoscopic and pharmacological therapy as a secondary prophylaxis (beta-blockers or carvedilol + repeated injection of tissue adhesives until the erradication of the fundal varices).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Early TIPS</intervention_name>
    <description>TIPS (first 5 days)</description>
    <arm_group_label>Early TIPS</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients developing acute variceal bleeding from GOV2 and/or IGV1 defined according to
        Baveno II criteria, admitted in the Hospital and receiving standard combined medical
        therapy (somatostatin 3 mg/12h continuous IV infusion or terlipressin, 2mg/4h IV +
        endoscopic injection of tissue adhesives as per center protocol).

        Exclusion Criteria:

          -  Hepatocarcinoma without therapeutic options (according to Milan criteria).

          -  Portal or mesenteric vein thrombosis avoiding the performance of TIPS.

          -  Acute alcoholic hepatitis.

          -  Platelet count &lt; 20.000/mm3.

          -  Previous treatment with portosystemic shunt.

          -  Pregnancy.

          -  Previous inclusion in the current study.

          -  Terminal liver disease (bilirrubin &gt; 10 mg/dL and/or prothrombin index &lt; 30%); or
             other fatal non-liver diseases.

          -  Denied informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angels Escorsell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Senior Consultant. Liver Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angels Escorsell, MD</last_name>
    <phone>34932275400</phone>
    <phone_ext>4030</phone_ext>
    <email>aescor@clinic.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Catalonia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Morillas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICU Liver Unit. Hospital Clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angels Escorsell, MD</last_name>
      <phone>34932275400</phone>
      <phone_ext>4030</phone_ext>
      <email>aescor@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Angels Escorsell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Càndid Villanueva, MD</last_name>
      <email>cvillanueva@santpau.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Carrión, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carles Aracil, MD</last_name>
      <email>carbla34@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W; Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007 Sep;46(3):922-38. Erratum in: Hepatology. 2007 Dec;46(6):2052.</citation>
    <PMID>17879356</PMID>
  </reference>
  <reference>
    <citation>Garcia-Tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding--unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference. Hepatology. 2008 May;47(5):1764-72. doi: 10.1002/hep.22273.</citation>
    <PMID>18435460</PMID>
  </reference>
  <results_reference>
    <citation>García-Pagán JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, Abraldes JG, Nevens F, Vinel JP, Mössner J, Bosch J; Early TIPS (Transjugular Intrahepatic Portosystemic Shunt) Cooperative Study Group. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010 Jun 24;362(25):2370-9. doi: 10.1056/NEJMoa0910102.</citation>
    <PMID>20573925</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2015</study_first_submitted>
  <study_first_submitted_qc>February 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2015</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut d'Investigacions Biomèdiques August Pi i Sunyer</investigator_affiliation>
    <investigator_full_name>Àngels Escorsell</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>Bleeding gastric varices</keyword>
  <keyword>Transjugular intrahepatic portosystemic shunt (TIPS)</keyword>
  <keyword>Injection of adhesives</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

